Similar Papers

Paper Title
Journal
Date
Author
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena ...
The Lancet Oncology | VOL. 22
Salvatore Siena, et. al.Salvatore Siena ...
04 May 2021
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Salvatore Siena ... Takayuki Yoshino
Nature Communications | VOL. 15
Salvatore Siena, et. al.Salvatore Siena ... Takayuki Yoshino
25 Nov 2024
Abstract 327: Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers
Timothy P Diperi ... Gabriela Raso
Cancer Research | VOL. 82
Timothy P Diperi, et. al.Timothy P Diperi ... Gabriela Raso
15 Jun 2022
Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer.
Ian Chau
The Lancet. Oncology | VOL. 22
Ian ChauIan Chau
04 May 2021
View more papers

More From: Nature Communications

Paper Title
Journal
Date
Author
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Salvatore Siena ... Takayuki Yoshino
Nature Communications | VOL. 16
Salvatore Siena, et. al.Salvatore Siena ... Takayuki Yoshino
15 Jan 2025
A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment
Sandra Viz-Lasheras ...
Nature Communications | VOL. 16
Sandra Viz-Lasheras, et. al.Sandra Viz-Lasheras ...
15 Jan 2025
A comprehensive assessment of current methods for measuring metacognition
Dobromir Rahnev
Nature Communications | VOL. 16
Dobromir RahnevDobromir Rahnev
15 Jan 2025
Integration of ordered porous materials for targeted three-component gas separation
Xue Jiang ... Kai-Jie Chen
Nature Communications | VOL. 16
Xue Jiang, et. al.Xue Jiang ... Kai-Jie Chen
15 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.